[go: up one dir, main page]

GB807826A - Derivatives of pyrimido[5,4-d] pyrimidine and production thereof - Google Patents

Derivatives of pyrimido[5,4-d] pyrimidine and production thereof

Info

Publication number
GB807826A
GB807826A GB8017/56A GB801756A GB807826A GB 807826 A GB807826 A GB 807826A GB 8017/56 A GB8017/56 A GB 8017/56A GB 801756 A GB801756 A GB 801756A GB 807826 A GB807826 A GB 807826A
Authority
GB
United Kingdom
Prior art keywords
bis
pyrimidopyrimidine
reacted
morpholino
heated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB8017/56A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Publication of GB807826A publication Critical patent/GB807826A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention comprises pyrimido [5,4-d] pyrimidines substituted in at least one of the 2-, 4-, 6- and 8-positions by one or more of the following atoms or groups: halogen (e.g. Cl, Br, I), amino, mono- or di-substituted amino (e.g. mono- or di-alkyl- or -aryl-amino), ether (e.g. alkoxy, aryloxy), thiol, thioether (e.g. alkylmercapto, carboxyalkylmercapto, arylmercapto), hydrazino, guanidino or heterocyclic groups, which groups may in turn be substituted; and the preparation of pyrimido [5,4-d] pyrimidine derivatives by reacting compounds of the general formula <FORM:0807826/IV (b)/1> (wherein at least one of the symbols R1-R4, which may be the same or different, represents a halogen atom and the remainder hydrogen, a substituted hydroxy group, an amino or thiol group or the residue of a heterocyclic ring) with compounds of the general formula H-R or MeI-R (wherein R represents bromine, iodine, a substituted hydroxy group, a free or substituted amino, thiol, guanidino or hydrazino group or the residue of a heterocyclic ring, and MeI represents an alkali metal atom). The reaction is advantageously carried out at - 20 DEG to 250 DEG C. (if necessary under pressure) in an inert solvent and diluent and in the presence of an acid-binding agent (e.g. an alkali metal hydroxide or carbonate, a tertiary amine, or excess of the second reaction component when suitable) and/or a reaction accelerator (e.g. of the Friedel-Crafts type) and/or copper powder, copper salts or strong inorganic acids as catalysts. When the starting material has more than one halogen atom available for exchange, the reaction may be carried out stepwise. In some cases also, not only halogen but also other substituents (e.g. free or substituted hydroxy or amino groups) may be replaced by the residue R. Suitable reactants H-R and MeI-R are alcohols, phenols, mercaptans, thiophenols, alkali metal alcoholates, phenolates, hydrosulphides and thiophenolates, ammonia, primary and secondary amines, guanidines, hydrazines, aminoalcohols, morpholine, piperidine and sodium iodide. In examples: (1) 4:6:8-trichloropyrimidopyrimidine is reacted with 6 molecular proportions of sodium methoxide in methanol to produce 4:6:8-trimethoxypyrimidopyrimide; (2) tetrachloropyrimidopyrimidine is reacted in dioxan with 4 molecular proportions of ammonia and various amines to replace the chlorine atoms in the 4- and 8-positions by the residues of the amino compounds, viz. N-hydroxyethylanilino, morpholino, p-chloranilino, b -hydroxyethylamino, b -diethylaminoethylamino, methyldodecylamino, isoamylamino, benzylamino, p - dimethylaminoanilino, diallylamino, methylcyclohexylamino, b -chlorethylamino, butylethanolamino, benzylethanolamino, 2:3 - dihydroxypropylamino, amino and carbethoxymethylamino; (3) 2:4:6:8 - tetrachloropyrimidopyrimidine is boiled with sodium iodide in acetone to produce 2:6-dichloro - 4:8 - diiodopyrimidopyrimidine; (4) the product of (3) is reacted with 4 molecular proportions of aniline in dioxan and benzene to form 2:6 - dichloro - 4:8 - dianilinopyrimidopyrimidine; (5) 2:4:6:8 - tetrachloropyrimidopyrimidine is refluxed with excess of aniline to give 2:4:6:8 - tetra-anilinopyrimidopyrimidine; the starting material may be replaced by 2:6-dichloro-4:8-dianilino-, -diamino-, -dihydroxy- or -dipiperidino-pyrimidopyrimidine; (6) 6-chloro-4:8-diiodopyrimidopyrimidine is reacted with 2.3-molecular proportions of morpholine and 2 molecular proportions of triethylamine in dioxan to produce 6 - chloro - 4:8 - dimorpholinopyrimidopyrimidine; (7) various 6-chloro-4:8-diaminopyrimidopyrimidines are heated (where necessary under pressure) with various amines to form 6 - morpholino - 4:8 - bis - (diethylamino) -, 6 - methylamino- and 6-morpholino-4:8-bis-(ethylamino) -, 6 - morpholino - 4:8 - di - (ethylethanolamino) -, 6 - anilino -, 6 - dimethylamino - and 6 - morpholino - 4:8 - diamino -, 6 - diethanolamino - 4:8 - bis - (allylamino) -, 6 - diethanolamino - 4:8 - dipiperidino -, 6 - (b - hydroxyethylamino) -, 6 - diisopropanolamino - and 6 - diethanolamino - 4:8 - dimorpholino -, 6 - methylethanolamino - 4:8 - bis - (methylamino) -, 6 - morpholino - 4:8 - di - (g - methoxypropylamino) -, 6 - diethanolamino - 4:8 - di - (p - nitroanilino) - and 6 - piperidino - 4:8 - di - (b - hydroxyethylamino) - pyrimidopyrimidine; (8) 2:4:6:8 - tetrachloropyrimidopyrimidine is reacted under vigorous conditions with excess of ammonia and various amines to replace all four chlorine atoms by dimethylamino, allylamino, methylethanolamino, b -hydroxyethylamino, piperidino, morpholino, p-chloranilino, amino and methylamino; (9) 4:6:8 - trichloropyrimidopyrimidine is reacted as in (2) to replace the chlorine atoms in the 4- and 8-positions by allylamino, methylethanolamino, diisopropylamino, methylamino, diethanolamino, p-nitroanilino, 3-methoxypropylamino, o-methoxyanilino, dibenzylamino, ethyleneimino and semicarbazido; (10) 2:6-dichloro - 4:8 - bis - (diethylamino) - pyrimidopyrimidine is refluxed with a solution of sodium in b -dimethylaminoethanol to produce 2:6-bis-(b - diethylaminoethoxy) - 4:8 - bis - (diethylamino) - pyrimidopyrimidine; (11) 4:6:8 - trichloro - 2 - thiopyrimidopyrimidine is reacted with 4 molecular proportions of morpholine in dioxan to form 6-chloro-2-thio-4:8-dimorpholinopyrimidopyrimidine; (12) piperidine similarly yields the corresponding dipiperidino compound; (13) 6 - methylthio - 2:4 - dichloropyrimidopyrimidine is reacted with excess of morpholine to produce 6-methylthio-2:4-dimorpholinopyrimidopyrimidine; (14) 2:6-dichloro - 4:8 - bis - (b - diethylaminoethylamino)-pyrimidopyrimidine is heated under pressure with sodium ethoxide in ethanol to replace the chlorine atoms by ethoxy groups; (15) 2:4:6:8-tetrachloropyrimidopyrimidine is heated with 4 molecular proportions of phenol and 2 of sodium carbonate to form 2:4:6:8-tetraphenoxypyrimidopyrimidine; (16) 2:4:6:8-tetrachloropyrimidopyrimidine is reacted with 4 molecular proportions each of thiophenol and sodium hydroxide in moist dioxan to give 2:4:6:8 - tetraphenylthiopyrimidopyrimidine; (17) 2:4:6:8-tetrachloropyrimidopyrimidine is refluxed with excess of sodium hydrosulphide in dimethylformamide to replace the chlorine atoms by thiol groups; (18) 2:4:6:8-tetrachloropyrimidopyrimidine is reacted with 6 molecular proportions of ethyl mercaptan and 2 of pyridine to produce 2:6-dichloro-4:8-diethylthiopyrimidopyrimidine; (19) 4:8 - dichloropyrimidopyrimidine is reacted as in (2) to replace the chlorine atoms by morpholino, piperidino, anilino, amino, methylamino, dimethylamino, hydrazino, N:N1-diphenylguanidino, b - hydroxyethylamino and N-hydroxyethyl - p - nitroanilino; (20) 4:8-dichloropyrimidopyrimidine is reacted with potassium hydrosulphide in alcohol and dioxan to produce 4:8-dithiopyrimidopyrimidine; (21) the product of (18) is heated under pressure with morpholine in aqueous copper sulphate solution to form 2:6-dimorpholino-4:8-diethylthiopyrimidopyrimidine; (22) 2:4:6:8 - tetrachloropyrimidopyrimidine is heated with excess of ethyl mercaptan and pyridine in dioxan to give 2:4:6:8 - tetraethylthiopyrimidopyrimidine; (23) 6 - chloro - 4:8 - di - (carboxymethylthio) - pyrimidopyrimidine is heated with morpholine to produce 6 - morpholino - 4:8 - di - (carboxymethylthio) - pyrimidopyrimidine; (24) 4:6:8-trichloropyrimidopyrimidine is heated under pressure with excess of thioglycollic acid and pyridine to produce 4:6:8-tri-(carboxymethylthio) - pyrimidopyrimidine; (25) 6-chloro-4:8-di - (propylamino) - pyrimidopyrimidine similarly yields 6-carboxymethylthio-4:8-di-(propylamino) - pyrimidopyrimidine; (26) various 2:6 - dichloro - 4:8 - diaminopyrimidopyrimidines are heated with various amines to form 2:6 - bis - (diethanolamino) - 4:8 - dipiperidino-, -4:8-bis-(diethylamino)-, -4:8-dipyrrolidino-, -4:8-bis-(diallylamino)-, -4:8-bis-(dimethylamino)-, -4:8-bis-(dibutylamino)- and -4:8-dimorpholino-, 2:6 - di - (methylethanolamino) - 4:8-dipiperidino- and -4:8-di-(dodecylethanolamino)-, 2:6 - di - (propylethanolamino) - 4:8 - dimorpholino-, and 2:6 - bis - (diisopropylamino) - 4:8 - dipiperidino - pyrimidopyrimidine; (27) similarly prepared, but at higher temperatures under pressure, are 2:6-dimorpholino - 4:8 - di - (ethylethanolamino) -, 4:8 - di - (propylethanolamino) -, - 4:8 - di - (methylethanolamino) -, - 4:8 - bis - (diethanolamino) - and - 4:8 - bis - (dimethylamino) -, 2:6 - dipiperidino - 4:8 - bis - (diethanolamino) -, - 4:8-bis - (isoamylamino) -, - 4:8 - dipyrrolidino - and -4:8-di-(benzylethanolamino)-, and 2:6-bis - (diethylamino) - 4:8 - bis - (diethanolamino) - pyrimidopyrimidine; (28) 2:4:6 - trichloropyrimidopyrimidine is heated (in some cases under pressure and in the presence of copper salts) with excess of various amines to replace all three chlorine atoms by methylamino, ethylamino, propylamino, dimethylamino, b -hydroxyethylamino, morpholino, anilino, p-chloroanilino and o-methoxyanilino; (29) 6 - chloro - 4:8 - dimorpholinopyrimidopyrimidine is heated (if desired under pressure) with various sodium alkoxide solutions to replace the chlorine atom by ethoxy, butoxy, b -diethylaminoethoxy, b -ethoxyethoxy and b -propoxyethoxy; (30) 2:6-dichloro-4:8-di-(b -propoxyethoxy) - pyrimidopyrimidine is heated with morpholine under pressure to give 2:6-dimorpholino - 4:8 - di - (b - propoxyethoxy) - pyrimidopyrimidine. Additional starting materials and products are listed. Starting materials. Halogen-substituted pyrimidopyrimidines are obtainable by (a) halogenation of the corresponding hydroxy compounds (e.g. the starting materials of Examples (1), (3), (5), (11), (13) and (19) are prepared by the action of PCl5 and/or POCl3 on, respectively, 4:6:8 - trihydroxy-, 3 - methyl - 2:6:8 - trihydroxy - 4 - oxo - 3:4 - dihydro -, 2:6 - dichloro - 4:8 - dihydroxy -, 4:6:8 - trihydroxy-2-thio-, 6-methylthio-2:4-dihydroxy-
GB8017/56A 1955-03-14 1956-03-14 Derivatives of pyrimido[5,4-d] pyrimidine and production thereof Expired GB807826A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE807826X 1955-03-14

Publications (1)

Publication Number Publication Date
GB807826A true GB807826A (en) 1959-01-21

Family

ID=6722936

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8017/56A Expired GB807826A (en) 1955-03-14 1956-03-14 Derivatives of pyrimido[5,4-d] pyrimidine and production thereof

Country Status (1)

Country Link
GB (1) GB807826A (en)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031450A (en) * 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
US3074928A (en) * 1959-06-25 1963-01-22 Thomae Gmbh Dr K Basic-substituted pyrimido-[5,4-d]-pyrimidines
US4478833A (en) * 1980-12-27 1984-10-23 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Trisubstituted pyrimido[5,4-d]pyrimidines and salts thereof
US4963541A (en) * 1989-02-22 1990-10-16 Abbott Laboratories Pyrimido-pyrimidine lipoxygenase inhibiting compounds
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6156528A (en) * 1997-05-30 2000-12-05 Cell Pathways, Inc Methods for using a phosphodiesterase in pharmaceutical screening to identify compounds for treatment of neoplasia
US6177471B1 (en) 1999-01-29 2001-01-23 Cell Pathways, Inc. Method for treating patients with acne by administering a CGMP-specific PDE inhibitor
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6500610B1 (en) 1997-05-30 2002-12-31 Cell Pathways, Inc Methods for identifying compounds for inhibiting of neoplastic lesions, and pharmaceutical compositions containing such compounds
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
US7115647B2 (en) 1998-01-14 2006-10-03 Osi Pharmaceuticals, Inc. Method of inhibiting neoplastic cells with indole derivatives
JP2007008929A (en) * 2005-06-28 2007-01-18 Samsung Electronics Co Ltd Pyrimidopyrimidine derivative, organic thin film transistor using the same, and method for producing the same
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US7989462B2 (en) 2003-07-03 2011-08-02 Myrexis, Inc. 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP2392567A1 (en) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazine derivatives and their use as lxr modulators
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN118993902A (en) * 2024-07-12 2024-11-22 波米科技有限公司 Fluorenyl-containing crosslinking agent, preparation method and application

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031450A (en) * 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
US3074928A (en) * 1959-06-25 1963-01-22 Thomae Gmbh Dr K Basic-substituted pyrimido-[5,4-d]-pyrimidines
US4478833A (en) * 1980-12-27 1984-10-23 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Trisubstituted pyrimido[5,4-d]pyrimidines and salts thereof
US4963541A (en) * 1989-02-22 1990-10-16 Abbott Laboratories Pyrimido-pyrimidine lipoxygenase inhibiting compounds
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6156528A (en) * 1997-05-30 2000-12-05 Cell Pathways, Inc Methods for using a phosphodiesterase in pharmaceutical screening to identify compounds for treatment of neoplasia
US6500610B1 (en) 1997-05-30 2002-12-31 Cell Pathways, Inc Methods for identifying compounds for inhibiting of neoplastic lesions, and pharmaceutical compositions containing such compounds
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US7115647B2 (en) 1998-01-14 2006-10-03 Osi Pharmaceuticals, Inc. Method of inhibiting neoplastic cells with indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6440981B1 (en) 1998-09-11 2002-08-27 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6177471B1 (en) 1999-01-29 2001-01-23 Cell Pathways, Inc. Method for treating patients with acne by administering a CGMP-specific PDE inhibitor
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US7989462B2 (en) 2003-07-03 2011-08-02 Myrexis, Inc. 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
JP2007008929A (en) * 2005-06-28 2007-01-18 Samsung Electronics Co Ltd Pyrimidopyrimidine derivative, organic thin film transistor using the same, and method for producing the same
EP2392567A1 (en) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazine derivatives and their use as lxr modulators
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
EP4470609A2 (en) 2019-01-18 2024-12-04 Astrazeneca AB Pcsk9 inhibitors and methods of use thereof
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN118993902A (en) * 2024-07-12 2024-11-22 波米科技有限公司 Fluorenyl-containing crosslinking agent, preparation method and application

Similar Documents

Publication Publication Date Title
GB807826A (en) Derivatives of pyrimido[5,4-d] pyrimidine and production thereof
US3272811A (en) Dihydrothieno-[3, 4-d]-pyrimidines
US2779780A (en) 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
Koppel et al. Pyrimidines. I. Synthesis of Pyrimidinethiols1, 2
GB1077689A (en) Derivatives of 3-methylpurine and methods of preparing the same
Robins Potential Purine Antagonists. IX. Further Studies of Some 4, 6-Disubstituted Pyrazolo [3, 4-d] pyrimidines1
Hendry et al. 68. New cytotoxic agents with tumour-inhibitory activity. Part I. Some aziridinopyrimidine derivatives
Russell et al. A Synthesis of 4-Amino-2-thiopyrimidines
US3113942A (en) Mono-alkyl ethers of tris (2-hydroxyphenyl) triazines
US3082206A (en) Novel 4-(p-aminobenzenesulphonamido)-2:6-diphenoxypyrimidines
US3498984A (en) 4-amino-2-phenyl-6-thiopyrimidines
MONTGOMERY et al. 7-Substituted 7H-Purines1
GB699812A (en) Manufacture of substituted pyrimidones
US3505331A (en) Process for preparing 2,4-diamino-7-chloropyrido(2,3-d)pyrimidines
GB565501A (en) Manufacture of para-amino-benzene-sulphonamido-pyrimidines
US3207756A (en) Manufacture of herbicidal 2-methylthio-4, 6-bis-amino-s-triazine derivatives
Maggiolo The Reaction of Thiocyanogen with Nitrogen Heterocycles; Pyridines, Pyrmidines and Quinolines1
KR870011106A (en) Method for preparing pyrimidine derivative
ROTH et al. 5-Arylthiopyrimidines. II. 2-and 4-Alkylamino and 4-Amino Derivatives1
Greenbaum et al. 6-Uracilsulfonic Acid, a Sulronic Acid Analog of Orotic Acid1
FI57400B (en) PROCEDURE FOR FRAMSTAELLNING AV 2,4-DIAMINO-5-BENZYLPYRIMIDINE
GB1152883A (en) 4,5-Polymethylene-Pyrimidine Derivatives
GB774095A (en) Improvements in or relating to pyrimidine compounds
Makisumi Synthesis of Potential Anticancer Agents. V. 6-Halo-s-triazolo [2, 3-a] pyrimidines.
GB1042295A (en) Novel 4-sulfanilamido-pyrimidines and their salts and processes for the manufacture thereof